Open

A Phase III Multicenter Randomized Trial to Study HQP1351 in Patients with Chronic Myeloid Leukemia (CML)

To Study the effects of HQP1351 in Patients with Chronic Myeloid Leukemia

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

Depending on the visit, you will meet with a study team member to go through a variety of tests such as a physical examination, pregnancy test, patient diary, ECG, ECHO, bone marrow, questionnaires, and medication compliance assessments.

In-person visits:
5-10

Total length of participation:
2 years

Looking for Specific Volunteers

Able to participate:

You have Chronic Myeloid Leukemia
You have been treated with 2 or more Tyrosine Kinase Inhibitors (TKIs)
Have T315I Mutation
Are not pregnant

Not eligible if:

You have any other form of Leukemia
You are under 18
You do not have T315I Mutation

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Joshua Zeidner
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

24-1003

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.